Immediate Impact

1 from Science/Nature 52 standout
Sub-graph 1 of 24

Citing Papers

Translating p53-based therapies for cancer into the clinic
2024 Standout
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
2 intermediate papers

Works of Els Lierman being referenced

The ability of sorafenib to inhibit oncogenic PDGFR  and FLT3 mutants and overcome resistance to other small molecule inhibitors
2007
Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant
2006

Author Peers

Author Last Decade Papers Cites
Els Lierman 189 204 154 154 19 448
Bernadette Guerton 186 104 163 117 13 419
Linda M. Bavisotto 126 122 101 170 18 394
Hideo Hyodo 296 66 211 212 17 503
Benjamin Hébraud 186 165 82 212 24 495
Ayumi Okuyama 45 202 98 95 22 435
Feiyan Wang 136 43 137 135 27 384
Alessia Moro 200 107 253 177 17 406
N. Rinaldi 54 213 37 73 16 456
M Shtalrid 308 81 214 67 28 459
Marjan Daneshpouy 142 70 53 99 12 499

All Works

Loading papers...

Rankless by CCL
2026